Cynata Therapeutics Future Growth

Future criteria checks 2/6

Cynata Therapeutics is forecast to grow earnings and revenue by 34.1% and 70.4% per annum respectively while EPS is expected to grow by 54.2% per annum.

Key information

34.1%

Earnings growth rate

54.2%

EPS growth rate

Biotechs earnings growth	15.3%
Revenue growth rate	70.4%
Future return on equity	n/a
Analyst coverage	Low
Last updated	05 Aug 2024

Recent future growth updates

Recent updates

We're Interested To See How Cynata Therapeutics (ASX:CYP) Uses Its Cash Hoard To Grow

Feb 02

We Think Cynata Therapeutics (ASX:CYP) Can Easily Afford To Drive Business Growth

Sep 09

Here's Why We're Not At All Concerned With Cynata Therapeutics' (ASX:CYP) Cash Burn Situation

May 26

Here's Why We're Not Too Worried About Cynata Therapeutics' (ASX:CYP) Cash Burn Situation

Dec 31

We're Not Worried About Cynata Therapeutics' (ASX:CYP) Cash Burn

Aug 11

Earnings and Revenue Growth Forecasts

ASX:CYP - Analysts future estimates and past financials data (AUD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
6/30/2026	7	-5	-4	-4	1
6/30/2025	1	-8	-8	-8	1
6/30/2024	2	-10	-10	-10	N/A
3/31/2024	2	-12	-11	-11	N/A
12/31/2023	2	-14	-12	-12	N/A
9/30/2023	2	-14	-13	-13	N/A
6/30/2023	2	-14	-14	-14	N/A
3/31/2023	2	-12	-12	-12	N/A
12/31/2022	3	-9	-10	-10	N/A
9/30/2022	5	-7	-7	-7	N/A
6/30/2022	8	-5	-3	-3	N/A
3/31/2022	8	-5	-2	-2	N/A
12/31/2021	8	-4	-1	-1	N/A
9/30/2021	5	-6	-3	-3	N/A
6/30/2021	2	-8	-5	-5	N/A
3/31/2021	2	-7	-5	-5	N/A
12/31/2020	3	-6	-5	-5	N/A
9/30/2020	5	-5	-4	-4	N/A
6/30/2020	7	-4	-3	-3	N/A
3/31/2020	6	-6	-5	-5	N/A
12/31/2019	4	-8	-7	-7	N/A
9/30/2019	3	-8	-7	-7	N/A
6/30/2019	1	-8	-7	-7	N/A
3/31/2019	1	-7	-6	-6	N/A
12/31/2018	1	-6	-5	-5	N/A
9/30/2018	1	-5	-4	-4	N/A
6/30/2018	1	-5	-4	-4	N/A
3/31/2018	1	-5	N/A	-4	N/A
12/31/2017	1	-5	N/A	-5	N/A
9/30/2017	2	-5	N/A	-4	N/A
6/30/2017	2	-5	N/A	-4	N/A
3/31/2017	2	-4	N/A	-3	N/A
12/31/2016	2	-3	N/A	-2	N/A
9/30/2016	1	-4	N/A	-3	N/A
6/30/2016	1	-5	N/A	-4	N/A
3/31/2016	1	-5	N/A	-4	N/A
12/31/2015	1	-5	N/A	-4	N/A
9/30/2015	1	-4	N/A	-4	N/A
6/30/2015	0	-4	N/A	-3	N/A
3/31/2015	0	-3	N/A	-2	N/A
12/31/2014	0	-3	N/A	-2	N/A
9/30/2014	0	-3	N/A	-2	N/A
6/30/2014	0	-3	N/A	-2	N/A
3/31/2014	0	-3	N/A	-1	N/A
12/31/2013	0	-2	N/A	-1	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: CYP is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: CYP is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: CYP is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: CYP's revenue (70.4% per year) is forecast to grow faster than the Australian market (5.7% per year).

High Growth Revenue: CYP's revenue (70.4% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if CYP's Return on Equity is forecast to be high in 3 years time

Cynata Therapeutics Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Price target decreased to AU$2.00

Recent updates

Cynata Therapeutics Limited, Annual General Meeting, Nov 19, 2024

Here's Why We're Watching Cynata Therapeutics' (ASX:CYP) Cash Burn Situation

New major risk - Financial position

Will Cynata Therapeutics (ASX:CYP) Spend Its Cash Wisely?

Cynata Therapeutics Limited Completes Patient Enrolment in CYP-006TK Diabetic Foot Ulcer Clinical Trial

Cynata Therapeutics Limited Announces Updates on Phase 2 Clinical Trial of CYP-001

New minor risk - Financial position

We're A Little Worried About Cynata Therapeutics' (ASX:CYP) Cash Burn Rate

Cynata Therapeutics Limited Announces Resignation of David Atkins as Director

New major risk - Financial position

Cynata Therapeutics Limited Announces Management Appointments

We're Interested To See How Cynata Therapeutics (ASX:CYP) Uses Its Cash Hoard To Grow

Cynata Therapeutics Limited Receives IRB Approval for Proposed aGvHD Phase 2 Clinical Trial

Cynata Therapeutics Limited Receives Notice of Acceptance from IP Australia for Novel Application of Cymerus MSCs

LUMC to Fund New Clinical Trial of Cynata's Cymerus™ MSCs in Kidney Transplantation

Cynata Therapeutics Limited Receives Notice of Allowance for Australia & Canada Cymerus Patents

Cynata Therapeutics Limited Announces Successful Completion of Planned DSMB Review of DFU Trial

Cynata Therapeutics Limited, Annual General Meeting, Nov 22, 2022

Cynata Therapeutics Limited Receives Grant Award to Fund Study of Cynata Mscs in Heart Disease from Australian Government National Health and Medical Research Council

We Think Cynata Therapeutics (ASX:CYP) Can Easily Afford To Drive Business Growth

Cynata Therapeutics Limited Appoints Janine Rolfe as Independent Non-Executive Director, Effective 1 September 2022

Cynata Therapeutics Limited Announces Preclinical Study Showing Optimisation of CymerusTM MSCs for Coronary Artery Disease Published in Leading Peer-Reviewed Journal

Cynata Therapeutics Limited Receives Notice of Allowance from US Patent Office for Use of the Cymerus MSCs in Asthma

Cynata Therapeutics Limited Announces the Completion of A Pre-Clinical Study That Has Provided Further Evidence in Support of the Highly Potent Anti-Inflammatory Effects of Cynata's Proprietary Cymerus MSCs

Cynata Therapeutics Limited Adds New Site for MEMD Clinical Trial

United States Food and Drug Administration Clears IND for Cynata Therapeutics Limited's Phase 2 Clinical Trial of CYP-001 in GvHD

Here's Why We're Not At All Concerned With Cynata Therapeutics' (ASX:CYP) Cash Burn Situation

Price target decreased to AU$2.00

Cynata Therapeutics Limited Advances Clinical Trial in Diabetic Foot Ulcers

Cynata Therapeutics Limited Receives Decision to Grant A Patent in Japan

Cynata Therapeutics Limited Receives Decision to Grant A Patent in Japan

Here's Why We're Not Too Worried About Cynata Therapeutics' (ASX:CYP) Cash Burn Situation

Cynata Therapeutics Limited Commences DFU Clinical Trial

We're Not Worried About Cynata Therapeutics' (ASX:CYP) Cash Burn

Cynata Therapeutics Limited Receives Approval by the Central Adelaide Local Health Network Human Research Ethics Committee to Commence A Clinical Trial

Cynata Therapeutics Limited Progresses Toward Clinical Trial in Diabetic Foot Ulcers

Cynata Therapeutics Limited Announces First Patient Enrolled in Cynata Mend Clinical Trial

Cynata Therapeutics Limited to Investigate New Study of the High Potency of Cymerus MSCs

New 90-day low: AU$0.64

New 90-day low: AU$0.66

New 90-day low: AU$0.74

Cynata Therapeutics Limited Announces Phase 3 Osteoarthritis Clinical Trial Commences

Cynata Therapeutics Limited Announces Positive Efficacy Data from A Study of Cymerustm Mesenchymal Stem Cells

New 90-day high: AU$1.03

New 90-day high - AU$0.79

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies